Table 1.
Basic information included in the literature.
| Author | Year | Age | M/F | Duration (wk) | Treatment | Control | Patient/diagnosis | Evaluation indicator | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Cases | Statins | Cases | Measures | |||||||
| Joy[19] | 2017 | T: 56.7 ± 9.9 | 5/7 | 24 | 6 | Sitagliptin | 6 | Placebo | NASH/ | ALT, AST, weight, TG, |
| C: 54.7 ± 9.8 | 100 mg/d | Liver biopsy | AP, BMI, GGT, HDL-C | |||||||
| LDL-C | ||||||||||
| Nelson[20] | 2009 | T: 52.6 ± 8.6 | 11/5 | 48 | 10 | Simvastatin | 6 | Placebo | NASH/ | ALT, AST, BMI, AP, |
| C: 52.5 ± 13.0 | 40 mg/d | Liver biopsy | TG, TC, LDL | |||||||
| Athyros[21] | 2006 | T: 59 ± 13 | 80/43 | 54 | 61 | Atorvastatin | 62 | Fenofibrate | NAFLD/ | Weight, ALT, AST, |
| C: 61 ± 12 | 20 mg/d | +RT | Liver biopsy and | GGT, AP, TG, TC, | ||||||
| +Fenofibrate | ultrasonography | LDL-C, HDL-C | ||||||||
| +RT | ||||||||||
| Alam[22] | 2018 | T: 41.7 ± 9.1 | 12/28 | 48 | 20 | Sitagliptin | 20 | RT | NASH/ | ALT, AST, GGT, BMI, |
| C: 35.5 ± 6.9 | 100 mg/d | Liver biopsy | Weight, TG, LDL, | |||||||
| +RT | HDL, AP | |||||||||
| Samy[23] | 2011 | 46.6 ± 5.56 | 22/28 | 32 | 25 | Atorvastatin | 25 | RT | NAFLD/ | TG, TC, LDL, HDL |
| 40 mg/d + RT | Liver biopsy and | |||||||||
| ultrasonography | ||||||||||
| Smits[24] | 2016 | T: 61.5 ± 1.7 | 27/7 | 12 | 17 | Sitagliptin | 17 | Placebo | NAFLD/ | HbA1c, Weight, BMI, |
| C: 65.8 ± 1.4 | 100 mg/d | Liver biopsy | ALT, AST, AP, GGT | |||||||
| Peng[25] | 2013 | T: 48.63 ± 5.24 | 45/35 | 24 | 40 | Simvastatin | 40 | RT | NAFLD/ | Total effective rate |
| C: 48.37 ± 6.03 | 40 mg/d + RT | Liver biopsy and | TG, TC, | |||||||
| Ultrasonography | ||||||||||
| Xu[26] | 2015 | 35–64 | 65/25 | 12 | 45 | Lovastatin | 45 | RT | NAFLD/ | ALT, GGT, TG, TC, |
| 20 mg/d + RT | Ultrasonography | Total effective rate | ||||||||
| You[27] | 2011 | 24–64 | 86/29 | 16 | 57 | Atorvastatin | 58 | RT | NAFLD/ | TG, TC, LDL-C, HDL-C |
| 20 mg/d + RT | Ultrasonography | Total effective rate | ||||||||
| Bi[28] | 2016 | T: 58.47 ± 2.51 | 66/34 | 24 | 50 | Atorvastatin | 50 | RT | NAFLD/ | ALT, AST, TG, TC, |
| C: 58.54 ± 2.46 | 20 mg/d + RT | Ultrasonography | LDL-C, HDL-C, BMI, | |||||||
| HbA1c | ||||||||||
| Qin[29] | 2013 | T: 51.50 ± 10.20 | 89/29 | 24 | 61 | Atorvastatin | 57 | RT | NAFLD/ | BMI, ALT, AST, FPG, |
| C: 52.20 ± 9.60 | 20 mg/d + RT | Ultrasonography | TG, TC, LDL-C, HDL-C | |||||||
| Lai[30] | 2012 | T: 48.71 ± 11.02 | 58/2 | 36 | 30 | Simvastatin | 30 | Placebo | NAFLD/ | ALT, AST, GGT |
| C: 48.59 ± 11.97 | 10 mg/d | Ultrasonography | total effective rate | |||||||
| Jiang[31] | 2018 | T: 44.62 ± 8.14 | 51/37 | 12 | 44 | Fluvastatin | 44 | RT | NAFLD/ | ALT, AST, TC, TG, BMI, |
| C: 43.64 ± 7.84 | 40 mg/d + RT | Ultrasonography | Total effective rate, LDL-C, HDL-C | |||||||
| Li[32] | 2011 | 21–60 | 48/32 | 12 | 40 | Atorvastatin | 40 | RT | NAFLD/ | ALT, AST, GGT, TG, |
| 10 mg/d + RT | Ultrasonography | TC, LDL-C, HDL-C | ||||||||
ALT = alanine aminotransferase, AP = alkaline phosphatase, AST = aspartate transaminase, BMI = body mass index, GGT = gamma-glutamyl transpeptidase, HbA1c = glycated hemoglobin, HDL-C = high-density lipoprotein-cholesterol, LDL-C = low-density lipoprotein-cholesterol, NAFLD = nonalcoholic fatty liver disease, NASH = nonalcoholic steatohepatitis, TC = total cholesterol, TG = triglyceride.